David Harpole, MD / Nicolas Girard, MD, PhD - Trials and Tribulations: Examining the Data for Perioperative Immunotherapeutic Approaches in Resectable NSCLC

Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Leveraging Precise Targets to Elevate Outcomes: NSCLC Treatment Strategies for HER2-Directed ADCs

Jia Ruan, MD, PhD - Clinical Case Challenges in Frontline PTCL: Navigating the Landscape of CD30-Positive PTCL Treatment

Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice

Jacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs

Richard Kim, MD / Gerald Prager, MD - Evidence-Based Strategies for Optimizing Long-Term Treatment Responses in Later Lines of mCRC Care

Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma

Joyce O'Shaughnessy, MD - Harnessing Immunotherapy for Early Breast Cancer Management: Neoadjuvant Updates in HR-Positive, HER2-Negative Disease

Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens

David M. Miller, MD, PhD / Todd Schlesinger, MD - A Clinician’s Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies

Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization

Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions

Aditya Bardia, MD - From Theory to Practice: Enhancing Antibody-Drug Conjugate Integration in HER2-Low Advanced Breast Cancer

John L. Marshall, MD - Proactive Safety Management Strategies to Extend Survival for Patients With Metastatic CRC

Rami Komrokji, MD - Navigating the First-Line Treatment Landscape of Anemia in Lower-Risk MDS: Translating the Latest Data to Practice

Stephanie E. Combs, MD / Heather Wakelee, MD - A Growing Need for Targeted Approaches in Unresectable Stage III NSCLC: A Clinical Evaluation of Evolving Data in EGFR Mutation–Positive Disease

Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice

Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective

Sagar Lonial, MD, FACP - Accelerating Targeted Degradation in Multiple Myeloma: The Role of CELMoDs in Overcoming IMiD Resistance in Earlier Lines of Therapy

Paul Telfer, MA, DM, BM, BCh, FRCP, FRCPath - Decoding the Future: Bringing Gene Therapy Into Prime Time for Patients With Sickle Cell Disease